PT  - JOURNAL ARTICLE
AU  - Beck, Erin S
AU  - Mullins, W Andrew
AU  - Silva, Jonadab dos Santos
AU  - Filippini, Stefano
AU  - Parvathaneni, Prasanna
AU  - Maranzano, Josefina
AU  - Morrison, Mark
AU  - Suto, Daniel J
AU  - Donnay, Corinne
AU  - Dieckhaus, Henry
AU  - Luciano, Nicholas J
AU  - Sharma, Kanika
AU  - Gaitán, María Ines
AU  - Liu, Jiaen
AU  - de Zwart, Jacco A
AU  - van Gelderen, Peter
AU  - Cortese, Irene
AU  - Narayanan, Sridar
AU  - Duyn, Jeff H
AU  - Nair, Govind
AU  - Sati, Pascal
AU  - Reich, Daniel S
TI  - Cortical lesions uniquely predict motor disability accrual and form rarely in the absence of new white matter lesions in multiple sclerosis
AID  - 10.1101/2023.09.22.23295974
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.22.23295974
4099  - http://medrxiv.org/content/early/2023/09/25/2023.09.22.23295974.short
4100  - http://medrxiv.org/content/early/2023/09/25/2023.09.22.23295974.full
AB  - Background and objectives Cortical lesions (CL) are common in multiple sclerosis (MS) and associate with disability and progressive disease. We asked whether CL continue to form in people with stable white matter lesions (WML) and whether the association of CL with worsening disability relates to pre-existing or new CL.Methods A cohort of adults with MS were evaluated annually with 7 tesla (T) brain magnetic resonance imaging (MRI) and 3T brain and spine MRI for 2 years, and clinical assessments for 3 years. CL were identified on 7T images at each timepoint. WML and brain tissue segmentation were performed using 3T images at baseline and year 2.Results 59 adults with MS had ≥1 7T follow-up visit (mean follow-up time 2±0.5 years). 9 had “active” relapsing-remitting MS (RRMS), defined as new WML in the year prior to enrollment. Of the remaining 50, 33 had “stable” RRMS, 14 secondary progressive MS (SPMS), and 3 primary progressive MS. 16 total new CL formed in the active RRMS group (median 1, range 0-10), 7 in the stable RRMS group (median 0, range 0-5), and 4 in the progressive MS group (median 0, range 0-1) (p=0.006, stable RR vs PMS p=0.88). New CL were not associated with greater change in any individual disability measure or in a composite measure of disability worsening (worsening Expanded Disability Status Scale or 9-hole peg test or 25-foot timed walk). Baseline CL volume was higher in people with worsening disability (median 1010μl, range 13-9888 vs median 267μl, range 0-3539, p=0.001, adjusted for age and sex) and in individuals with RRMS who subsequently transitioned to SPMS (median 2183μl, range 270-9888 vs median 321μl, range 0-6392 in those who remained RRMS, p=0.01, adjusted for age and sex). Baseline WML volume was not associated with worsening disability or transition from RRMS to SPMS.Discussion CL formation is rare in people with stable WML, even in those with worsening disability. CL but not WML burden predicts future worsening of disability, suggesting that the relationship between CL and disability progression is related to long-term effects of lesions that form in the earlier stages of disease, rather than to ongoing lesion formation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health. Erin Beck was supported by a Clinician Scientist Development Award and a Career Transition Fellowship Award from the National Multiple Sclerosis Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of the National Institutes of Health gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors